Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ChemoMetec AS's Enterprise Value is kr6,085.9 Mil.
ChemoMetec AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr229.9 Mil. Therefore, ChemoMetec AS's EV-to-EBIT ratio for today is 26.47.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ChemoMetec AS's Enterprise Value is kr6,085.9 Mil.
ChemoMetec AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr257.9 Mil. Therefore, ChemoMetec AS's EV-to-EBITDA ratio for today is 23.60.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ChemoMetec AS's Enterprise Value is kr6,085.9 Mil.
ChemoMetec AS's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was kr493.1 Mil. Therefore, ChemoMetec AS's EV-to-Revenue ratio for today is 12.34.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, ChemoMetec AS's Enterprise Value is kr6,085.9 Mil.
ChemoMetec AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr132.7 Mil. Therefore, ChemoMetec AS's EV-to-FCF ratio for today is 45.85.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
ChemoMetec AS (OCSE:CHEMM) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
ChemoMetec AS's current Enterprise Value is kr6,085.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr229.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
ChemoMetec AS's current Enterprise Value is kr6,085.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr257.9 Mil.
ChemoMetec AS's current Enterprise Value is kr6,085.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was kr493.1 Mil.
ChemoMetec AS's current Enterprise Value is kr6,085.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was kr210.1 Mil.
ChemoMetec AS's current Enterprise Value is kr6,085.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr132.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS Enterprise Value Related Terms
ChemoMetec AS Enterprise Value Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, ChemoMetec AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Enterprise Value distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
ChemoMetec AS's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of kr6,085.9 Mil mean?
ChemoMetec AS (OCSE:CHEMM) has a Enterprise Value of kr6,085.9 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ChemoMetec AS and its competitors.
Is ChemoMetec AS's Enterprise Value too high?
ChemoMetec AS's current Enterprise Value is kr6,085.9 Mil. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Enterprise Value compare to ABT and SYK?
ChemoMetec AS's Enterprise Value of kr6,085.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ChemoMetec AS and its competitors. ChemoMetec AS's current Enterprise Value is kr6,085.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Significantly Undervalued. The stock's GF Value™ is kr523.33, compared to a current price of kr365.20 — trading 30.2% below its estimated fair value. The current Enterprise Value is kr6,085.9 Mil. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Enterprise Value is kr6,085.9 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr365.20 is trading 30.2% below its estimated GF Value™ of kr523.33.
GuruFocus considers ChemoMetec AS to be Significantly Undervalued.
Key valuation signals for OCSE:CHEMM:
Enterprise Value: kr6,085.9 Mil
GF Value™: kr523.33 vs. price of kr365.20 (30.2% below fair value)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
